Salix Pharmaceuticals Ltd Watch

from 8-K 4 pages First Supplemental Indenture

from 8-K 4 pages First Supplemental Indenture

from 8-K 3 pages $750,000,000 Salix Pharmaceuticals, Ltd. 6.00% Senior Notes Due 2021 Joinder to Registration Rights Agreement

from 8-K 5 pages Supplemental Indenture

from 8-K 29 pages $750,000,000 Salix Pharmaceuticals, Ltd. 6.00% Senior Notes Due 2021 Registration Rights Agreement

from 8-K 19 pages Escrow and Security Agreement

from 8-K 114 pages Salix Pharmaceuticals, Ltd. 6.00% Senior Notes Due 2021 Indenture Dated as of December 27, 2013 U.S. Bank National Association, as Trustee

from 8-K 110 pages Salix Pharmaceuticals, Ltd. as Issuer and U.S. Bank National Association as Trustee Indenture Dated as of March 16, 2012 1.5% Convertible Senior Notes Due 2019

from 8-K 3 pages First Supplemental Indenture

from S-3ASR 104 pages Salix Pharmaceuticals, Ltd. as Issuer and U.S. Bank National Association as Trustee Indenture Dated as of May [—], 2010 [ ]% Convertible Senior Notes Due 2015

from S-3ASR 8 pages A-1 Salix Pharmaceuticals, Ltd. [ ]% Convertible Senior Note Due 2015

from S-3ASR 2 pages This Certificate and the Shares Represented Hereby Are Issued and Shall Be Held Subject to All the Provisions of the Certificate of Incorporation and the Bylaws of the Corporation and Any Amendments Thereto, to All of Which the Holder of This Certificate, by Acceptance Hereof, Assents. a Statement of the Rights, Preferences, Privileges and Restrictions Granted to or Imposed Upon the Shares of the Corporation and Upon the Holders Thereof May Be Obtained by Any Stockholder Upon Request and Without Charge at the Principal Office of the Corporation. the Bylaws of the Corporation Contain Restrictions on the Transfer of Shares of the Corporation. for Value Received, Hereby Sell, Assign and Transfer Unto Shares Represented by the Within Certificate, and Do Hereby Irrevocably Constitute and Appoint Attorney to Transfer the Said Shares on the Books of the Within Named Corporation With Full Power of Substitution in the Premises. Dated A.D. 20 in Presence of Notice. the Signature of This Assignment Must Correspond With the Name as Written Upon the Face of the Certificate, in Every Particular, Without Alteration or Enlargement, or Any Change Whatever

from 8-K 127 pages Salix Pharmaceuticals, Ltd. as Issuer and U.S. Bank National Association as Trustee Indenture Dated as of August 22, 2008 5.5% Convertible Senior Notes Due 2028

from 8-K 7 pages Certificate of Designation of Series a Junior Participating Preferred Stock of Salix Pharmaceuticals, Ltd

from S-1/A 1 page Form of Common Share Certificate

from S-1 ~10 pages Form of Warrant to Purchase Common Shares

from S-1 ~5 pages Form of Warrant to Purchase Common Shares